biotikur was created for people who want to understand their health and improve it. One of our core values is to boldly create evidence-based products through logic, reason, and hard science.
In addition to conducting our own research, we’ve compiled a library of references and peer-reviewed studies from world-renowned labs and institutions as a resource for our fellow skeptics.
Learn more about how probiotics and a healthy gut biome contribute to your wider health.
[The following scientific research is for informational use only. Information included, referenced or linked to by biotikur should not be used to diagnose, prevent, treat or cure any disease. Consult your doctor before taking nutritional supplements.]
Research Supporting Colorectal Application of Probiotics
biotikur is designed to maximize the concentration of probiotics introduced to the gut, thereby promoting a stronger long-term gut-biome balancing effect. Whereas oral administration limits the number of viable probiotics delivered to the gut biome, direct colorectal delivery of pre and probiotics in conjunction with oral synbiotic capsules can safely deliver enough viable, colonizing probiotics to the lower sigmoid colon (where 80% of gut bacteria reside) and make a significant difference in the balance of your gut.
The beneficial effects of colorectal administration of probiotics directly to the gut have been demonstrated in placebo-controlled randomized controlled trials (RCTs).
Browse Research by Benefit:
Below you’ll find selected studies demonstrating observed relationships between the gut biome characteristics (e.g. presence and proportion of probiotics, microbiota diversity, presence of pathogenic bacteria) and various health endpoints.
Scientific research is nuanced and dynamic. We recognize this by classifying each product based upon a review of existing research. Our evaluation criteria includes the number of studies, consistency of results, magnitude of results, and methodology characteristics.
M = Mixed. This means that some studies have shown positive results while others have been less conclusive.
E = Emerging. This means that the evidence is from pre-clinical studies, studies in rodents or studies with small sample sizes.
S = Strong. This means there have been high-quality studies performed with positive results.
[Human] = Research, studies and trials have been performed on humans
[Mice] = Research, studies and trials have been performed on mice
[Human/Mice] = Human microbiota samples were transferred into mice to observe effect
[Review] = Researchers reviewed multiple studies/trials to arrive at qualitative judgments or conclusions
- Diabetes (Type 2)
- Inflammatory Bowel Disease (IBD) - Crohn’s Disease and Ulcerative Colitis
- Mental Health
- Obesity and Adiposity
Scientific Advisory Board
Isabel Sousa MsC, PhD (Candidate)
Isabel is a trained biochemist and is completing her PhD in Nutritional Sciences at the Technical University of Munich. Isabel researched and wrote her dissertation on the common genetics between Type 2 Diabetes patients and sufferers of Alzheimer's disease.
Isabel was also a visiting researcher at the Broad Institute of MIT and Harvard University in 2017, where she developed a new CRISPR/Cas9 gene editing method allowing for scalable and accurate single nucleotide variant editing. Isabel is enthusiastic about translating life science research into impactful products.
Dr. med. Johann Banzhaf
Dr. Banzhaf completed his medical studies at Charité Berlin (PhD) and performed his doctoral research on obsessive-compulsive disorder. Dr. Banzhaf trained as a general practitioner with an emphasis on emergency medicine, specializing in pediatrics and surgical rescue.
Dr. Banzhaf also completed rotations in general internal medicine in Wittenberg and emergency medicine at Charité Mitte. Dr. Banzhaf has also completed several exchanges in Spain, the United States and Switzerland.
Dr. Banzhaf is currently in private practice in Bad Saarow, Germany.
Ana Neves PharmD
Ana is currently Global Head of Marketing and Business Management at Carl Zeiss Meditec AG. Prior to moving into a leadership role at Zeiss, Ana spent twenty years in Strategy, Marketing Excellence and Regulatory Affairs at Bayer Healthcare.
Ana received her PharmD from the University of Lisbon as well as her MBA from the Universidade Católica Portuguesa. Ana is passionate about creating new business models and evidence-based product experiences.